Polku Therapeutics Named VC Favorite at Prestigious Health Design Pitch Competition
October 16, 2024
Polku Therapeutics is proud to announce its recognition as the VC Favorite at the recent Health Design Pitch Competition, an event showcasing innovative life science companies transforming healthcare. This prestigious competition brings together leading venture capitalists, industry experts, and promising startups to identify and celebrate groundbreaking solutions addressing critical healthcare challenges.
The recognition highlights Polku Therapeutics' pioneering work in developing disease-modifying therapies for neurodegenerative disorders, a field with an urgent need for innovation. Polku's cutting-edge approach, including its focus on two key protein targets—prolyl oligopeptidase (PREP) and protein phosphatase 2A (PP2A)—has set a new benchmark in the pursuit of effective treatments for conditions like Parkinson's disease, Alzheimer's disease, and tauopathies.
The competition served as a platform to present Polku Therapeutics' mission, scientific breakthroughs, and promising pipeline to an audience of influential investors and peers. The VC Favorite award is a testament to the potential of Polku's innovative therapies to revolutionize care for patients suffering from these debilitating disorders.
More about Health Design event https://www.healthdesign.io/
